Morgan Stanley lowered the firm’s price target on Eli Lilly (LLY) to $1,124 from $1,146 and keeps an Overweight rating on the shares. The firm ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Eli Lilly (LLY) stock gains as Goldman Sachs upgrades it to Buy from Neutral citing the company's leadership position in the ...

Indiana’s appetite for economic growth continues to shape policy at a rapid pace — and that’s becoming a problem.

The bill aims to address concerns over water transfers like those planned to serve the controversial LEAP industrial district ...

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

Relying on a wicked curveball, the right hander recorded eight strikeouts and allowed just three hits over four innings ...

Electricity demand for Indiana's LEAP project has doubled, with Eli Lilly & Co. and Meta as tenants. New power lines and infrastructure are needed.